Alterity Therapeutics Limited Stock Shares Outstanding
| PRNAF Stock | USD 0 0.00 0.00% |
Fundamental analysis of Alterity Therapeutics allows traders to better anticipate movements in Alterity Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Alterity |
Alterity Therapeutics Limited Company Shares Outstanding Analysis
Alterity Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Current Alterity Therapeutics Shares Outstanding | 2.41 B |
Most of Alterity Therapeutics' fundamental indicators, such as Shares Outstanding, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Alterity Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
| Competition |
Based on the latest financial disclosure, Alterity Therapeutics Limited has 2.41 B of shares currently outstending. This is much higher than that of the Healthcare sector and significantly higher than that of the Biotechnology industry. The shares outstanding for all United States stocks is significantly lower than that of the firm.
Alterity Shares Outstanding Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Alterity Therapeutics' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Alterity Therapeutics could also be used in its relative valuation, which is a method of valuing Alterity Therapeutics by comparing valuation metrics of similar companies.Alterity Therapeutics is currently under evaluation in shares outstanding category among its peers.
Alterity Fundamentals
| Return On Equity | -0.39 | |||
| Return On Asset | -0.26 | |||
| Profit Margin | (2.51) % | |||
| Operating Margin | (3.03) % | |||
| Current Valuation | (7.2 M) | |||
| Shares Outstanding | 2.41 B | |||
| Shares Owned By Insiders | 15.14 % | |||
| Shares Owned By Institutions | 0.33 % | |||
| Price To Earning | 0.88 X | |||
| Price To Book | 0.67 X | |||
| Price To Sales | 3.12 X | |||
| Gross Profit | 4.76 M | |||
| EBITDA | (15.08 M) | |||
| Net Income | (12.85 M) | |||
| Cash And Equivalents | 34.81 M | |||
| Cash Per Share | 0.01 X | |||
| Total Debt | 117.49 K | |||
| Debt To Equity | 0 % | |||
| Current Ratio | 7.07 X | |||
| Book Value Per Share | 0.01 X | |||
| Cash Flow From Operations | (12.34 M) | |||
| Earnings Per Share | (0) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.87 | |||
| Market Capitalization | 18.77 M | |||
| Total Asset | 41.36 M | |||
| Retained Earnings | (125 M) | |||
| Working Capital | 32 M | |||
| Current Asset | 34 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 91.2 | |||
| Net Asset | 41.36 M |
About Alterity Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Alterity Therapeutics Limited's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Alterity Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Alterity Therapeutics Limited based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| USOI | Credit Suisse X Links | |
| ULTY | Tidal Trust II | |
| CONY | YieldMax N Option | |
| BCAT | BlackRock Capital Allocation | |
| PDI | Pimco Dynamic Income |
Other Information on Investing in Alterity Pink Sheet
Alterity Therapeutics financial ratios help investors to determine whether Alterity Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Alterity with respect to the benefits of owning Alterity Therapeutics security.